Abstract:Editorial for “T1 Mapping on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Oxaliplatin-Induced Liver Injury in a Mouse Model” Oxaliplatin (OXA) is a third-generation platinum commonly used antitumor drug and is used in the treatment of gastrointestinal cancers. The most common use is seen in colorectal cancers followed by the gastric, liver, and pancreatic cancers. OXA is a cisplatin derivative and has less renal toxicity compared with cisplatin. However, there are many studies showing significant damage to nontumor-bearing liver. This damage evaluation is now being done by a T1 mapping of the gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) contrast study by magnetic resonance imaging (MRI). This is a newer, novel concept for risk assessment and injury evaluation being done in a mouse model. The results show significant potential for liver injury evaluation. OXA is more a commonly used antitumor drug for various cancers in mouse models. This chemotherapeutic agent has involved many studies for various grades of the hepatic injury in the normal liver. The most common presentation is so-called sinusoidal obstruction syndrome (SOS). SOS is significantly characterized by obliteration and dilatation of the liver sinusoids due to collagenization of the perisinusoidal space. This is due to erythrocyte extravasation and hepatocyte plate disruption. These changes can cause inhibition of future remnant liver hypertrophy following portal vein embolization, increased risk of intraoperative bleeding and transfusion rate, intrahepatic sinus platelet aggregation, hepatocyte atrophy and necrosis, hepatic steatosis, steatohepatitis, intrahepatic sinus haemorrhage, and sinusoidal obstruction syndrome hepatomegaly with pain, splenomegaly, ascites, hepatic vein narrowing (HVN), and gall bladder wall thickening and an increased rate of liver insufficiency and ultimately may lead to hepatectomy. In the early form this can be misinterpreted as metastases. Thus, early diagnosis of SOS by imaging is important for the management of patients prior to surgery and during follow-up. These changes are difficult to evaluate by routine imaging. Gd-EOB-DTPA is a commonly used MR contrast agent for T1weighted images. 6 After intravenous injection, Gd-EOB-DTPA is cleared by biliary excretion and renal excretion. Gd-EOB DTPA is taken up by hepatocytes and excreted via the biliary pathway. In this issue, Yang et al, report that GdEOB-DTPA has a T1-shortening effect, so the measurement of the T1 relaxation time of liver parenchyma before and after GdEOB-DTPA administration allows quantitative evaluation of Gd-EOB-DTPA uptake by the liver parenchyma, thus reflecting liver function. Thus, with this same concept, it was described in a mouse model of the efficacy of this contrast agent. Organic anion-transporting polypeptide (OATP) is known to mediate the uptake of Gd-EOB-DTPA by hepatocytes and multidrug resistance protein (MRP), which further mediates biliary excretion of Gd-EOBDTPA. Reduced reduction rates of T1 relaxation time in liver fibrosis may be explained by a hypofunction of OATP and fewer normalfunctioning hepatocytes. After Gd-EOB-DTPA injection, the beginning of the hepatocyte uptake could be identified at 1.5 minutes and 50% of the administered dose was transported into the hepatocytes at 20 minutes. Therefore, the imaging at 20 minutes after Gd-EOB-DTPA injection was used as a “standard” hepatobiliary phase (HBP) to assess liver lesions and function. The HBP imaging obtained at 10 minutes is a feasible timepoint for replacing 20-minute HBP imaging after Gd-EOB-DTPA injection to diagnose liver lesion with a 3.0T MRI system. The reason here is that the MRI signal-to-noise ratio (SNR) can be expected to increase by twofold at 3.0T than 1.5T, and the contrast-to noise ratio (CNR) also would be improved. The mouse model study shows liver function and injury after OXA therapy. This shows the significant importance of the T1 mapping in the successful evaluation of liver injury. This again will be able to differentiate from metastases, also especially in the early stages.

Potential of Gd-EOB-DTPA As an Imaging Biomarker for Liver Injury Estimation after Radiation Therapy

Gd-Eob-Dtpa-Enhanced Liver Magnetic Resonance Imaging As Image Biomarker for Assessment of Liver Injury after External Beam Radiation Therapy

Biochemical Metabolic Changes Assessed By31p Magnetic Resonance Spectroscopy after Radiation-Induced Hepatic Injury in Rabbits

Application Values of Gadolinium-ethoxybenzyl Diethylenetriaminepentaacetic Acid Enhanced Magnetic Resonance Imaging-based Radiomics in the Quantitative Assessment of Liver Reserve Function of Patients with Liver Cirrhosis

Editorial for “T1 Mapping on Gd‐EOB‐DTPA‐Enhanced MRI for the Prediction of Oxaliplatin‐Induced Liver Injury in a Mouse Model”

Regional Liver Function Assessment Using Free-breathing T1 Mapping in Gadoxetic Acid–enhanced MRI for Patients with Bile Duct Cancer: A Prospective Study

[The Value of Gd-EOB-DTPA-enhanced MRI in Patients with Major Resection of Liver Cancer].

Gd-EOB-DTPA-enhanced Magnetic Resonance Imaging for Focal Liver Lesions in Chinese Patients: a Multicenter, Open-Label, Phase III Study.

Gd-BOPTA enhanced MRI in evaluation of reserved liver function

Potential of Gd-EOB-DTPA-enhanced MR imaging for evaluation of bile duct ligation-induced liver injury in rabbits

Assessing Liver Function in Liver Tumors Patients: the Performance of T1 Mapping and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI

Gd+-EOB-DTPA-enhanced MRI evaluation of colorectal liver metastases and chemotherapy-induced fatty liver

Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury

Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests

Is Liver-Specific Gadoxetic Acid-Enhanced Magnetic Resonance Imaging a Reliable Tool for Detection of Hepatocellular Carcinoma in Patients with Chronic Liver Disease?

Gadoxetate-disodium-enhanced Magnetic Resonance Imaging for Liver Fibrosis Staging: a Systematic Review and Meta-Analysis

A Novel Method Using Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetate Acid-Enhanced Magnetic Resonance Imaging for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients with a Major Portal Vein Tumor Thrombus

[Evaluation of clinical safety and diagnostic efficacy of domestic liver-specific magnetic resonance contrast agent (gadoxetate disodium)]

Assessment of Liver Fibrosis Using T1 Mapping on Gd-EOB-DTPA-enhanced Magnetic Resonance.

Comparison of the Ability of Gadobenate Dimeglumine and Gadolinium Ethoxybenzyl Dimeglumine to Display the major Features for Noninvasively Diagnosing Hepatocellular Carcinoma According to the LI-RADS 2018v

Assessing Liver Function by T1 Maps on Gd-EOB-DTPA-Enhanced MRI for up to 50 Min in Rat Models of Liver Fibrosis: A Longer Hepatobiliary Time Period may Help